In vitro diagnostics and blood-based biomarker testing
Strategic Profile
The company's operating segments include Breast Cancer Test, Alzheimer's, and COVID-19 testing. With minimal current revenue generation and a highly diluted share structure, the company appears to be in an early-stage or struggling commercialization phase.
Cyborg Score Rationale
As of May 2026, the stock trades at near-zero valuations with minimal market capitalization and legacy operations that have not demonstrated meaningful revenue traction. The company faces significant execution and capitalization challenges typical of micro-cap diagnostics firms.
Top Insights
Market cap collapsed to approximately $14K as of May 2026, indicating severe distress or potential delisting risk
Company is founded in 2010 but has not achieved significant scale with reported single-digit millions in revenue
Operating in competitive in vitro diagnostics space with focus on oncology and neurodegenerative disease detection
All revenue generation is US-based despite Israeli headquarters location
Named Competitors
Foundation Medicine — Molecular oncology testing and precision medicine
Guardant Health — Circulating tumor DNA and liquid biopsy testing